5a-Reductase is an NADPH-dependent enzyme responsible for the conversion of testosterone to (DHT) which is an active agonist for androgen receptor. Benign prostatic hyperplasia (BPH), skin disorders such as acne, male pattern baldness and hirsutism are androgen-related disorders, associated with elevated levels of DHT.
5a-Reductase is an NADPH-dependent enzyme responsible for the conversion of testosterone to (DHT) which is an active agonist for androgen receptor. Benign prostatic hyperplasia (BPH), skin disorders such as acne, male pattern baldness and hirsutism are androgen-related disorders, associated with elevated levels of DHT.
6) As a consequence, a 5a-reductase inhibitor is expected to provide a potential treatment for androgen-related disorders. Several 5a-reductase inhibitors have been reported, 7, 8) including both steroidal inhibitors, finasteride 7a) and epristeride, 7b) and a nonsteroidal inhibitor, ONO-3805 8a) (Chart 1). Following the discovery of these inhibitors, the existence of two different 5a-reductase isozymes, called type 1 and type 2 5a-reductases, have been reported in humans and rats. [9] [10] [11] The type 1 enzyme is normal in men with congenital 5a-reductase deficiency and is expressed in skin tissue throughout the body that has an optimal pH of between 6 and 9. The type 2 enzyme is defective in men with congenital 5a-reductase deficiency and is the dominant form of the enzyme in genital tissue, including prostate that has an optimal pH of about 5.5. However, the physiological role of these isozymes has yet to be fully elucidated. Steroidal inhibitors, for example, finasteride, have been shown to be clinically effective for the treatment of BPH, however, the possibility of adverse effects due to their steroidal structures remains. 12) On the other hand, nonsteroidal inhibitors have not shown clinical efficacy for the treatment of BPH. Finasteride showed strong inhibitory activity (IC 50 ϭ4.1 nM) 13) for human prostatic 5a-reductase, whereas ONO-3805 showed moderate activity (IC 50 ϭ 538 nM) 13) which might not be sufficient to show clinical efficacy. We considered that a more potent nonsteroidal inhibitor of human prostatic 5a-reductase than ONO-3805 could show clinical efficacy for the treatment of BPH and reduce the potential of side effects compared to steroidal inhibitors.
In our previous studies on novel human prostatic 5a-reductase inhibitors, we found the 4-(1H-indol-5-yl)oxy benzoic acid derivative, YM-32906 (1), which showed potent inhibitory activity with an IC 50 value of 0.44 nM.
2) However,
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Susumu IGARASHI,* Hiroshi INAMI, Hiromu HARA, 3) Hiroshi KOUTOKU, Hiroyuki ORITANI, 4) and Toshiyasu MASE 5) these indole derivatives showed reduced inhibitory activity for rat prostatic 5a-reductase and were not sufficient to show inhibitory activity in a rat in vivo model. 14) In this study, our attention focused on discovering novel benzoic acid derivatives having potent inhibitory activities for both human and rat prostatic 5a-reductases by the modification of the 1H-indol-5-yloxy group of 1. The indolin-5-yloxy group and 4-aminophenoxy group as the substituent at the 4-position of the benzoic acid moiety were newly designed as described in Chart 1. We now report the synthesis and the structure-activity relationships of these benzoic acid derivatives 2 and 3.
Chemistry The indoline derivatives (2a-2j) were prepared as described in Charts 2 and 3. Compound 4 was treated with diethyl pyrocarbonate and 4-dimethylaminopyridine (DMAP) to give compound 5. The reduction of the indole ring and the debenzylation were carried out by catalytic hydrogenation in the presence of Pd-C to afford compound 6, which was alkylated with 3-chloro-4-fluorobenzonitrile in the presence of K 2 CO 3 in N,N-dimethylformamide (DMF) and hydrolyzed with KOH to give the benzoic acid derivative 8. The esterification of 8 was performed using H 2 SO 4 in EtOH to afford compound 9, which was alkylated with benzyl bromide or (1-bromoethyl)benzene and subsequent hydrolysis with NaOH to give compounds 2a and 2b. Compound 2c was obtained by reductive alkylation of 8 in the presence of NaBH(OAc) 3 with 4-isopropylbenzaldehyde. Compound 11, prepared using the same procedure for the preparation of 6 with di-tert-butyl pyrocarbonate, was alkylated with 4-fluorobenzonitrile derivatives followed by the deprotection with CF 3 CO 2 H to give compound 12. Compounds 2d-2j were obtained by the N-alkylation of 12 with 2-(bromomethyl)naphthalene or aldehydes and subsequent hydrolysis with KOH.
The aniline derivatives (3a-3h) were prepared as described in Charts 4 and 5. The O-alkylation of the aminophenol derivatives 13 with 3-chloro-4-fluorobenzonitrile afforded 14, which was converted to the benzoic acids 3a, 3b and 3h in one or two steps as described in Chart 4. Compounds 3c-3g were prepared as described in Chart 5. Compound 15 was alkylated with 1-fluoro-4-nitrobenzene followed by a catalytic hydrogenation in the presence of RaneyNi to give 16. Compound 3e was obtained by the acylation with benzoyl chloride of 16 and subsequent hydrolysis with KOH. Compound 16 was alkylated with 2 eq of benzyl bromide followed by hydrolysis with NaOH to afford 3f. The reductive alkylation of 16 was performed using aldehydes in the presence of NaBH(OAc) 3 to give 17, which was methylated with formaldehyde in the presence of formic acid to afford 18. Compounds 17 and 18 were converted to the benzoic acids 3c, 3d and 3g by hydrolysis with NaOH.
Results and Discussion
The inhibitory activities of the indoline and aniline derivatives were evaluated on the basis of their ability to inhibit 5a-reductases in human prostate at pH 5.5 and rat prostate at pH 6.5, which are optimal for the activities of the type 2 enzymes. These results are described in Tables 1 and 2. In our previous paper, we found that the indole derivative, having a hydrophobic substituent such as the 4-phenoxybenzyl group at the 1-position of the indole ring, showed moderate inhibitory activity against the rat enzyme with an IC 50 value of 73 nM. 2) However, this indole derivative was not sufficient to show inhibitory activity in a rat in vivo model. Initially, the effects of substituents at the 1-position of the indoline ring were investigated as shown in Table 1 . The benzyl derivative 2a, the 1-phenylethyl derivative 2b, the 4-isopropylbenzyl derivative 2c and the naphthalen-2-ylmethyl derivative 2d showed potent inhibitory activities for the human enzyme with IC 50 values below 10 nM but no inhibitory activities for the rat enzyme at 300 nM. On the other hand, the 4-phenoxybenzyl derivative 2e retained its high potency for the human enzyme and showed moderate inhibitory activity for the rat enzyme with an IC 50 value of 46 nM. Furthermore, the 4-benzyloxybenzyl derivative 2f and the 4-(4-isopropylphenoxy)benzyl derivative 2g resulted in a loss in activity for the rat enzyme, suggesting that the 4-phenoxy-benzyl group plays an important role for showing potent inhibitory activity against the rat enzyme. Next, modification of the chloro group of compound 2e was investigated. Compound 2h, which has no substituent at the position, showed reduced activity, while the fluoro derivative 2i and the bromo derivative 2j retained potency for the rat enzyme. These findings suggested that a hydrophobic substituent at the 3-position of the benzoic acid moiety such as a halogen is favorable for the inhibitory activity against the rat enzyme.
Concerning the inhibitory activities of the aniline derivatives, the 4-anilinophenoxy derivatives (3a, 3b) and 4-benzylaminophenoxy derivatives (3c, 3d, 3f ) were selective human prostatic 5a-reductase inhibitors as shown in Table 2 . The Nmethylated compounds 3b and 3d showed more potent inhibitory activity compared to the parent compounds 3a and 3c, while the 4-benzoylaminophenoxy derivative 3e showed reduced potency and the 4-dibenzylaminophenoxy derivative 3f resulted in a slight loss of potency compared to compound 3c. These results suggested that a proton of the amino group is unfavorable and a hydrophobic and bulky substituent such as the dibenzylamino group is tolerant for the display of potent inhibitory activity against the human enzyme. On the other hand, the 4-[N-(4-phenoxybenzyl)amino]phenoxy derivatives (3g, 3h) resulted in potent inhibitory activities for both the human and rat enzymes. Compound 3g showed the most potent inhibitory activity against the rat enzyme in these aniline derivatives with an IC 50 value of 5.5 nM. These results suggested that the 4-phenoxybenzyl group of these aniline derivatives is also effective for providing potent inhibitory activity against the rat enzyme as shown by the indoline derivatives.
In order to investigate in vivo inhibitory activity of these indoline and aniline derivatives, compounds 2e, 2j, 3g, and 3h, which showed potent inhibitory activities for the rat enzyme, were evaluated for their inhibitory activity of the DHT concentration in rat prostate by oral administration. These results are described in Table 3 . In this model, (Ϯ)-ONO-3805 showed significant in vivo inhibitory activities at 10 mg/kg. The aniline derivative 3g, having a potent in vitro inhibitory activity for the rat enzyme, did not improve the in vivo inhibitory activity compared to (Ϯ)-ONO-3805. On the other hand, the indoline derivative 2e, having 18 times less potent in vitro inhibitory activity for the rat enzyme than (Ϯ)-ONO-3805, reduced prostatic DHT by 44% at a dose of 100 mg/kg. Since compound 2e showed 100 times more potent in vitro inhibitory activity for the human enzyme compared to (Ϯ)-ONO-3805, there is a possibility to show clinical efficacy for the treatment of BPH.
Conclusions
In order to prepare a novel potent inhibitor against both human and rat prostatic 5a-reductases, we modified the 1H-indol-5-yloxy group of YM-32906 to indolin-5-yloxy group or 4-aminophenoxy group. Consequently, we have identified a new series of indoline and aniline derivatives having a 4-phenoxybenzyl group as potent inhibitors for both human and rat prostatic 5a-reductases. Particularly, compound 2e (YM-36117) showed potent in vivo inhibitory activity on rat prostatic DHT. These derivatives have the possibility to display clinical efficacy for the treatment of BPH.
Experimental
Melting points were taken on a Yanaco MP-3 melting point apparatus and are uncorrected.
1 H-nuclear magnetic resonance ( 1 H-NMR) spectra were recorded on a JEOL FX-90, JNM-LA 300, JNM-LA 400, JNM-GX 400 or JNM-GX 500 spectrometer with tetramethylsilane as an internal standard. Mass spectra (MS) were recorded on a Hitachi M-80 (electron impact (EI)) or JEOL JMS-DX300 (FAB) mass spectrometer. Elemental analyses were performed with a Yanaco MT-5. Column chromatography was carried out on silica gel (Wakogel C-200). Unless otherwise noted, all reagents and solvents obtained from commercial suppliers were used without further purification. In general, the organic extract was dried over anhydrous Na 2 SO 4 or MgSO 4 , and the organic solvent was evaporated under reduced pressure. All nonaqueous reactions were performed in dry glassware under an atmosphere of dry Ar.
Ethyl 5-Benzyloxy-1H-indole-1-carboxylate (5) A mixture of 4 (6.70 g, 30.0 mmol), diethyl pyrocarbonate (5.84 g, 36.0 mmol) and DMAP (370 mg, 3.03 mmol) in 30 ml of CH 3 CN was stirred at room temperature for 15 h. After the reaction mixture was concentrated, the residue was extracted with AcOEt. The extract was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : AcOEtϭ95 : 5) to give 5 (5.38 g, 61%) as a colorless solid: 
. Ethyl 5-(2-Chloro-4-cyanophenoxy)indoline-1-carboxylate (7) A mixture of 6 (3.69 g, 17.8 mmol), 3-chloro-4-fluorobenzonitrile (2.91 g, 18.7 mmol) and K 2 CO 3 (3.69 g, 26.7 mmol) in 60 ml of DMF was stirred at 80°C for 5 h. After dilution with AcOEt, the reaction mixture was washed with water and brine, dried and concentrated. The residue was washed with EtOH to give 7 (5.72 g, 94%) as a colorless solid: 
NMR (CDCl
3 ) d: 1.38 (t, 3H, Jϭ7 Hz), 3.0-3.1 (m, 2H), 3.61 (t, 2H, Jϭ8 Hz).
4-[(1-Benzylindolin-5-yl)oxy]-3-chlorobenzoic Acid (2a)
A mixture of 9 (620 mg, 1.95 mmol), benzyl bromide (370 mg, 2.16 mmol), KI (10 mg, 0.06 mmol) and K 2 CO 3 (400 mg, 2.89 mmol) in 10 ml of DMF was stirred at room temperature for 2 h. After dilution with AcOEt, the reaction mixture was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : AcOEtϭ95 : 5) to give ethyl 4-[(1-benzylindolin-5-yl)oxy]-3-chlorobenzoate (590 mg, 74%) as a colorless oil. This intermediate (560 mg, 1.37 mmol) was dissolved in 9 ml of EtOH-dioxane (7 : 2), then 5 N NaOH aqueous solution (8 ml) was added, and the mixture was stirred at room temperature for 8 h. The reaction mixture was acidified with 3 N HCl aqueous solution and extracted with AcOEt. The extract was washed with water and brine, dried and concentrated, and the residue was recrystallized from EtOH to give 2a (270 mg, 52%) as gray crystals: mp 142-143°C; 
3-Chloro-4-{[1-(4-isopropylbenzyl)indolin-5-yl]oxy}benzoic Acid (2c)
A mixture of 8 (580 mg, 2.00 mmol), 4-isopropylbenzaldehyde (330 mg, 2.20 mmol), AcOH (120 mg, 2.00 mmol) and NaBH(OAc) 3 (640 mg, 3.00 mmol) in 20 ml of dichloroethane (20 ml) was stirred at room temperature for 4 h. The reaction mixture was quenched with water, neutralized with 1 N NaOH aqueous solution and extracted with AcOEt. The extract was washed with water and brine, dried and concentrated. 
3-Chloro-4-(indolin-5-yloxy)benzonitrile (12a)
A mixture of 11 ( 5.51 g, 23.5 mmol), 3-chloro-4-fluorobenzonitrile (3.83 g, 24.6 mmol) and K 2 CO 3 (4.86 g, 35.2 mmol) in 80 ml of DMF was stirred at 80°C for 2 h. After dilution with AcOEt, the reaction mixture was washed with water and brine, dried and concentrated. This intermediate (9.24 g) was dissolved in 100 ml of trifluoroacetic acid, and the mixture was stirred at room temperature for 1 h and concentrated. The residue was neutralized with 1 N NaOH aqueous solution and extracted with AcOEt. The extract was washed with water and brine, dried and concentrated, and the residue was recrystallized from EtOH to give 12a (5.14 g, 81%) as a colorless solid; Essentially the same procedure as described above for the preparation of 2e afforded 2f (brown crystals, 58%), 2g (colorless crystals, 63%), 2h (pale brown crystals, 59%), 2i (colorless crystals, 35%), and 2j (colorless crystals, 44%).
4-(4-Anilinophenoxy)-3-chlorobenzonitrile (14a)
Essentially the same procedure as described above for the preparation of 7 afforded 14a (90%) as a pale yellow solid; 
3-Chloro-4-[4-(N-methylanilino)phenoxy]benzoic Acid (3b)
To a suspension of 60% NaH (130 mg, 3.30 mmol) in 5 ml of DMF, 14a (960 mg, 3.00 mmol) was added, and stirred at room temperature for 1 h. Methyl iodide (510 mg, 3.60 mmol) was added and the mixture was stirred at room temperature for 22 h. After the addition of water, the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : AcOEtϭ95 : 5) to give 3-chloro-4-[4-(N-methylanilino)phenoxy]benzonitrile (860 mg, 87%) as a colorless solid. This intermediate (820 mg, 2.45 mmol) was dissolved in 15 ml of EtOH, then 15 ml of 8 N KOH aqueous solution was added, and the mixture was refluxed for 6 h. The reaction mixture was acidified with 3 N HCl aqueous solution and extracted with AcOEt. The extract was washed with water and brine, dried and concentrated, and the residue was washed from EtOH to give 3b (440 mg, 51%) as colorless crystals: mp 133-134°C; d, 1H, Jϭ9 Hz), 6.8-7.0 (m, 2H), 7.24 (t, 1H, Jϭ7 Hz) 
. Authentic Materials The 5a-reductase inhibitors, finasteride 7a) and (Ϯ)-ONO-3805, 8a) were synthesized in our company according to the methods described in the literature.
Biological Methods. Preparation of 5a a-Reductases from Rat Prostate and Human Prostate Male Wistar rats 8-12 weeks of age (Charles River Japan Inc., Atsugi, Japan) were sacrificed and the ventral prostates were removed. The prostatic tissues were rinsed with ice-cold saline and minced with scissors. Unless specified, all the following procedures were carried out at 4°C. The minced tissues were homogenized with a Polytron homogenizer (Kinematica GMBH, Lucerne, Switzerland) in 3 tissue volumes of 20 mM sodium phosphate buffer, pH 7.0, containing 0.25 M sucrose and 0.1 mM dithiothreitol (DTT). The homogenate was centrifuged at 10000ϫg for 10 min, and the resulting supernatant was centrifuged again at 140000ϫg for 60 min. The pellets were resuspended in 40 mM sodium phosphate buffer, pH 6.5. The suspension was stored at Ϫ80°C until use.
Human prostatic tissues from BPH patients who received a transurethral prostatectomy were kindly provided by Dr. T. Tahara at Yamato Hospital, Tokyo, Japan, and stored at Ϫ80°C until preparation of the enzyme fractions. The frozen prostatic tissues were minced with scissors and homogenized with a Polytron homogenizer in 3 tissue volumes of 10 mM Tris-HCl buffer, pH 7.0, containing 0.33 M sucrose, 1 mM DTT and 1 mM NADPH. The homogenate was centrifuged at 1000ϫg for 5 min. The supernatant was centrifuged at 11000ϫg for 20 min, and the resulting supernatant was centrifuged again at 140000ϫg for 60 min. The resulting pellet was resuspended in 10 mM Tris-HCl buffer, pH 7.0, and stored at Ϫ80°C until use. 5a a-Reductase Assay in Vitro 5a-Reductase activities were assayed according to the method described by Liang et al. 15) with a minor modification. Briefly, the reaction solutions contained in a final volume of 0.5 ml: 1 mM [4-14 C] testosterone, 1 mM DTT, 50 mM NADPH, 50 mM buffer (Tris-HCl, pH 6.5, for the rat prostate enzyme; Tris-citrate, pH 5.0, for the human prostate enzyme) and the enzyme fractions. To identify the inhibitory effect of the drugs, the various concentrations of the test compounds were also added in 5 ml DMSO (final conc. 1%). The reaction solutions in duplicate were incubated at 37°C for 60 min, and the reaction was terminated by the addition of 2.0 ml cold AcOEt containing 10 mg testosterone, 5a-DHT, 4-androstene-3,17-dione,5a-androstan-3a,17b-diol and 5a-androstan-3,17-dione as the standards. The organic phase was separated by centrifugation, evaporated under N 2 gas and resuspended with 40 ml AcOEt. 20 ml of AcOEt was spotted on the TLC plate and separated twice using AcOEt/cyclohexane (1 : 1) as the developing solvent. The steroid standards were located by UV (254 nm) and by spraying with a 1% CeSO 4 -10% H 2 SO 4 solution followed by heating. The regions containing 5a-reduced metabolites (5a-DHT, 5a-androstan3a,17b-diol and 5a-androstan-3,17-dione) were cut from the TLC plate, soaked in 5 ml of Aquasol-2 and the radioactivity was counted by a scintillation counter. The IC 50 values for 5a-reductase activity were obtained from the linear line drawn using the least-squares fitting method.
In Vivo Effects in Rats Male SD rats at 9 weeks of age (Charles River Japan Inc., Atsugi, Japan) were used to evaluate the effects of test compounds on the prostatic concentration of DHT. The test compounds or a vehicle were orally administered as an aqueous suspension with 0.5% methylcellulose. Eight hours after the dosing, the rat were sacrificed by chloroform anesthesia and the ventral prostate in the treated rats was removed and weighed. The ventral prostates were immediately placed in liquid nitrogen then stored at Ϫ80°C until use.
The frozen prostatic tissues (wet weight 200-500 mg) were minced with scissors and homogenized using a Polytron homogenizer in 3 ml of ice-cold water. One milliliter of the homogenate was twice extracted using 3 ml of ice-cold diethyl ether. The collected ether layer was concentrated under nitrogen gas and resuspended with 1.5 ml of assay buffer (50 mM Tris-HCl buffer, pH 8.0, containing 0.1% (w/v) gelatin). The DHT contents in the extract samples were determined by radioimmunoassay using testosterone/ DHT [ 3 H] assay system (Amersham Pharmacia Biotech, Uppsala, Sweden). The DHT contents were calculated as pg/100 mg of prostatic wet weight.
